Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Thomas Jefferson University (11)
- Department of Surgery (10)
- Humans (10)
- Poster (7)
- 19th Century (5)
-
- History (5)
- History, 19th Century (5)
- Male (5)
- Middle Aged (5)
- 20th Century (4)
- History, 20th Century (4)
- ECMO (3)
- Female (3)
- General Surgery (3)
- Philadelphia (3)
- Treatment Outcome (3)
- Adult (2)
- Aged (2)
- Carcinoma (2)
- Follow-Up Studies (2)
- Logistic Models (2)
- Multivariate Analysis (2)
- Pennsylvania (2)
- Survival Rate (2)
- 80 and over (1)
- A cost reducing ECMO model (1)
- A single institutional experience (1)
- Abdominal (1)
- Accidents (1)
- Accidents, Traffic (1)
- Publication
- File Type
Articles 31 - 32 of 32
Full-Text Articles in Medicine and Health Sciences
Extracorporeal Membranous Oxygenation Mimics Aortic Dissection On Cat Scan., Philip Batista, Nicholas C. Cavarocchi, Hitoshi Hirose
Extracorporeal Membranous Oxygenation Mimics Aortic Dissection On Cat Scan., Philip Batista, Nicholas C. Cavarocchi, Hitoshi Hirose
Department of Surgery Faculty Papers
A 66 year-old female presented with refractory acute congestive heart failure, cardiogenic shock, and ventricular tachyarrhythmia. Veno-arterial extracorporeal membrane oxygenation (ECMO) was placed via femoral cannulation for salvage and stabilized. CAT scan of the chest performed as a part of heart transplant work-up, demonstrated an unequal distribution of intravenous contrast in the aortic arch (Figure 1). Radiologist’s preliminary reading was of “aortic dissection” while in fact this is truly “normal ECMO flow”.
Targeted Therapies In The Treatment Of Advanced Hepatocellular Carcinoma., Zhengyu Wei, Cataldo Doria, Yuan Liu
Targeted Therapies In The Treatment Of Advanced Hepatocellular Carcinoma., Zhengyu Wei, Cataldo Doria, Yuan Liu
Department of Surgery Faculty Papers
Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option …